No OS benefit? No problem. FDA panel backs use of Lynparza in pancreatic cancer
As AstraZeneca works to tighten its hold on the PARP market, an independent panel of advisors to the FDA cautiously endorsed Lynparza’s use in certain …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
